Overall, the available information on the functions of PAK1, the experimental data from preclinical melanoma models, and the evidence from similarly treated non-melanoma cancers all point to PAK1 as a modulator of melanoma’s response to multiple types of anti-cancer therapy. This evidence concerns the gene PAK1 and melanoma.